Gene therapy startup snags $30M A round

The San Francisco-based gene therapy startup Audentes Therapeutics has rounded up an impressive $30 million A round. OrbiMed Advisors led the round with 5AM Ventures and Versant Ventures joining in. The money is earmarked for the development of AT001 for X-linked Myotubular Myopathy and AT002 for Pompe disease. Both AT001 and AT002 are based on adeno-associated virus gene therapy technology. "Our focused, experienced team is committed to advancing the promising scientific approach of gene therapy and looks forward to collaborating closely with our patient, research and medical community partners in this process," says CEO Matthew Patterson. Release